Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
6.037,59
1,06%
NASDAQ
20.020,36
-0,05%
Bitcoin
95.784,45
0,10%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Annexon Inc (ANNX) Annexon Inc (ANNX) Notizie

ANNX

Annexon (ANNX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ANNX
DataOraFonteTitoloSimboloCompagnia
19/12/202422:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ANNXAnnexon Inc
16/12/202413:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANNXAnnexon Inc
05/12/202400:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANNXAnnexon Inc
15/11/202400:46Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ANNXAnnexon Inc
14/11/202422:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANNXAnnexon Inc
08/11/202420:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ANNXAnnexon Inc
15/10/202420:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANNXAnnexon Inc
16/08/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ANNXAnnexon Inc
12/08/202422:59Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ANNXAnnexon Inc
07/06/202403:57Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ANNXAnnexon Inc
16/04/202415:00GlobeNewswire Inc.Turnstone Biologics Appoints William Waddill to its Board of DirectorsNASDAQ:ANNXAnnexon Inc
15/02/202402:46Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANNXAnnexon Inc
12/02/202422:24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANNXAnnexon Inc
23/01/202423:00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANNXAnnexon Inc
08/01/202402:00GlobeNewswire Inc.Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative DiseasesNASDAQ:ANNXAnnexon Inc
27/12/202312:30GlobeNewswire Inc.Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
22/12/202323:28Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ANNXAnnexon Inc
20/12/202323:27GlobeNewswire Inc.Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common StockNASDAQ:ANNXAnnexon Inc
20/12/202323:24Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:ANNXAnnexon Inc
20/12/202323:10GlobeNewswire Inc.Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary EndpointNASDAQ:ANNXAnnexon Inc
20/12/202323:08GlobeNewswire Inc.Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement PathwayNASDAQ:ANNXAnnexon Inc
18/12/202322:01GlobeNewswire Inc.Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ANNXAnnexon Inc
22/11/202322:01GlobeNewswire Inc.Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ANNXAnnexon Inc
13/11/202312:30GlobeNewswire Inc.Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial ResultsNASDAQ:ANNXAnnexon Inc
09/11/202312:30GlobeNewswire Inc.Annexon Biosciences to Participate in 2023 Jefferies London Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
24/10/202312:30GlobeNewswire Inc.Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic AtrophyNASDAQ:ANNXAnnexon Inc
10/10/202312:30GlobeNewswire Inc.Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)NASDAQ:ANNXAnnexon Inc
19/09/202312:30GlobeNewswire Inc.Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
18/09/202322:01GlobeNewswire Inc.Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ANNXAnnexon Inc
07/08/202312:30GlobeNewswire Inc.Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial ResultsNASDAQ:ANNXAnnexon Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ANNX

La tua Cronologia

NASDAQ
CORZ
Core Scientific
BIT
TINE
Tabula Us Enhanced Infla...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network